INT174232

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 36
Total Number 37
Disease Relevance 8.74
Pain Relevance 3.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PNP) small molecule metabolic process (PNP) cytoskeleton (PNP)
intracellular (PNP) cytoplasm (PNP)
Anatomy Link Frequency
eye 2
body 2
bands 1
internal 1
A549 1
PNP (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 219 100.00 Very High Very High Very High
backache 183 100.00 Very High Very High Very High
anesthesia 26 50.64 Quite High
methotrexate 26 48.52 Quite Low
adenocard 30 27.12 Quite Low
fibrosis 2 6.64 Low Low
Glutamate 30 5.00 Very Low Very Low Very Low
Paracetamol 24 5.00 Very Low Very Low Very Low
Potency 8 5.00 Very Low Very Low Very Low
alcohol 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Low Back Pain 183 100.00 Very High Very High Very High
Neck Pain 177 100.00 Very High Very High Very High
Ovarian Cancer 36 99.98 Very High Very High Very High
Cancer 354 99.76 Very High Very High Very High
Glioma 108 99.64 Very High Very High Very High
Hepatocellular Cancer 36 99.24 Very High Very High Very High
Sprains And Strains 10 99.08 Very High Very High Very High
Lung Cancer 6 93.82 High High
Cold Sores 216 82.32 Quite High
Influenza Virus Infection 56 81.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An episode of LBP and NP
Gene_expression (episode) of NP associated with pain and backache
1) Confidence 0.30 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2588446 Disease Relevance 1.27 Pain Relevance 1.27
An episode of LBP and NP is defined by the presence of LBP and NP during a recall period of 3 months followed and preceded by a recall period of 3 months without LBP and NP.
Gene_expression (presence) of NP associated with pain and backache
2) Confidence 0.30 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2588446 Disease Relevance 1.50 Pain Relevance 1.50
Third, all workers of the intervention and control departments are asked: 1) if they are aware of prioritised ergonomic measures and whether the ergonomic measures are implemented at the department; 2) if they actually use the ergonomic measures; and 3) about the perceived effectiveness of the implemented ergonomic measures on LBP and NP prevention.
Neg (prevention) Gene_expression (prevention) of NP associated with pain and backache
3) Confidence 0.30 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2588446 Disease Relevance 0.35 Pain Relevance 0.35
hepatocellular carcinoma cell lines (HepG2, Hep3B, and HuH-7) expressing PNP were highly sensitized to FAMP, showing IC50s of < 1??
Gene_expression (expressing) of PNP associated with hepatocellular cancer
4) Confidence 0.22 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 0.99 Pain Relevance 0
express PNP in only 0.1% of the cells after 5 days, yet treatment of these with MEP resulted in an average 49% reduction in tumor size and 30% increase in life span compared with control tumors [74].
Gene_expression (express) of PNP associated with cancer
5) Confidence 0.22 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 0.63 Pain Relevance 0
Human ovarian tumors transfected with E. coli PNP controlled by an SV40 promoter and implanted IP were shown to
Gene_expression (transfected) of PNP associated with ovarian cancer
6) Confidence 0.22 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 0.69 Pain Relevance 0
Human ovarian tumors transfected with E. coli PNP controlled by an SV40 promoter and implanted IP were shown to
Gene_expression (controlled) of PNP associated with ovarian cancer
7) Confidence 0.22 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 0.69 Pain Relevance 0
The most widely used prodrug for PNP in GDEPT is 6-methylpurine
Gene_expression (prodrug) of PNP
8) Confidence 0.22 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 0.67 Pain Relevance 0
FAMP showed good activity against sc D54MG glioma tumor xenografts expressing E. coli PNP, but was not quite as effective as MEP [77].
Gene_expression (expressing) of PNP associated with cancer and glioma
9) Confidence 0.20 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179761 Disease Relevance 1.01 Pain Relevance 0
For encapsulation efficiency determination, freshly prepared pSOD-HSA NP suspension was centrifuged at 48,000x g, 4 °C for 50 min.
Gene_expression (suspension) of NP
10) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
For in vitro release study, the NP pellet (containing around 300 ?
Gene_expression (pellet) of NP
11) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
The viability of HSA NP-treated cells was examined using MTT assay.
Gene_expression (viability) of NP
12) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
l of HSA NP suspension at a dose of 130 ng pSOD per eye, the fusion protein was detectable using western blot in all eyes injected with the nanoparticle formulation (Figure 8).
Gene_expression (eye) of NP in eye
13) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
At 20 mg/ml, free HSA reduced the cell-associated FITC-HSA NP by 50%.
Gene_expression (reduced) of NP
14) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
l of FITC-labeled pSOD-HSA NP suspension (0.1 mg/ml in serum-free medium) together with 100 ?
Gene_expression (suspension) of NP
15) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
FITC-labeled pSOD-HSA NP formulation was prepared following the procedures described in 2.3 except that 5 mg of FITC-labeled HSA was added into the HSA solution before NP preparation.
Gene_expression (solution) of NP
16) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
Interestingly, pSOD-HSA NP results in 86% transfection efficiency, indicating that the HSA NP formulation is about 6 fold more efficient than Lipofectamine.
Gene_expression (results) of NP
17) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
The results indicated 2% transfection efficiency, possibly due to the autofluorescence of glutaraldehyde modified protein, which is negligible compared to the transfection efficiency measures obtained with the plasmid containing HSA NP.
Gene_expression (containing) of NP
18) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
HSA NP (containing 1 ?
Gene_expression (containing) of NP
19) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0
Lyophilized blank HSA NP (prepared following the same protocols as pSOD-HSA NP, without the addition of pSOD) were dispersed to concentrations ranging from 5 to 5000 ?
Gene_expression (dispersed) of NP
20) Confidence 0.18 Published 2007 Journal Molecular Vision Section Body Doc Link PMC2768759 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox